Published in Health Business Week, November 17th, 2006
Under the terms of this agreement, Green Cross will fund all development, regulatory, manufacturing, and commercialization activities in South Korea for JX-594 and will pay Jennerex a royalty on commercial sales in South Korea. As part of the agreement, Jennerex is responsible for the clinical supply of JX-594 and Green Cross will have options to manufacture JX-594 to the South Korean market.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week